Compare UNCY & SPEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UNCY | SPEG |
|---|---|---|
| Founded | 2016 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.3M | 156.1M |
| IPO Year | 2021 | N/A |
| Metric | UNCY | SPEG |
|---|---|---|
| Price | $8.12 | $10.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $25.67 | N/A |
| AVG Volume (30 Days) | ★ 523.7K | 46.0K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $675,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $582.86 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.47 | $9.95 |
| 52 Week High | $8.74 | $11.03 |
| Indicator | UNCY | SPEG |
|---|---|---|
| Relative Strength Index (RSI) | 57.60 | 71.13 |
| Support Level | $5.95 | $10.16 |
| Resistance Level | $8.54 | $10.35 |
| Average True Range (ATR) | 0.44 | 0.00 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 55.04 | 100.00 |
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
Silver Pegasus Acquisition Corp is a blank check company.